Technical Name Integrative platform of biomarker analysis for cancer immunotherapy
Project Operator National Taiwan University Graduate Institute of Oncology
Project Host 楊志新
Summary
This project will establish a integrative platform of biomarker analysis incorporating all the major markers for efficacy prediction of cancer immunotherapy (including next-generation sequencing, transcriptome analysis of tumor micro-environment multiplex immunofluorescence staining, gut microbiome). This platform will be validated by prospective clinical trials of immunotherapy done by our team.
Scientific Breakthrough
目前國際臨床試驗所使用的生物指標﹝包括腫瘤PD-L1 蛋白表現量、癌細胞突變量 (mutation loads) 等﹞主要問題包括個別指標的療效預測能力不佳、不同指標所代表的臨床意義難以整合。
Industrial Applicability
此一整合性生物指標測試平台將可廣泛應用於各種癌症免疫治療的開發,鼓勵國際藥廠投注更多資源提升台灣癌症臨床試驗的能量,並可幫助未來臨床照護篩選合適的病患接受合適的治療。此一平台的整合技術經驗也將可以轉移到次世紀免疫治療效果之預測。
Keyword tumor micro-environment
Notes
  • Contact
other people also saw